COVID-19 vaccine-associated cerebral venous thrombosis in Germany
Preprint
- 4 May 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Objective Reports of cerebral sinus and venous thrombosis (CVT) after ChAdOx1 vaccination against SARS-CoV-2 have raised safety concerns. We aimed to estimate the incidence of CVT within one month from first dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany. Methods A web-based questionnaire was e-mailed to all Departments of Neurology. We asked to report cases of CVT within one month of a COVID-19 vaccination. Other cerebral events could also be reported. Incidence rates of CVT were calculated by using official statistics of nine German States. Results A total of 45 CVT cases were reported. In addition, 9 primary ischemic strokes, 4 primary intracerebral hemorrhages, and 4 other neurological events were recorded. Of the CVT patients, 35 (77.8%) were female, and 36 (80.0%) were below the age of 60 years. Fifty-three events were observed after vaccination with ChAdOx1 (85.5%), 9 after BNT162b2 (14.5%), and none after mRNA-1273 vaccination. After 7,126,434 first vaccine doses, the incidence rate of CVT within one month from first dose administration was 6.5 (95% CI, 4.4-9.2) per 100,000 person-years for all vaccines and 17.9 (11.8-26.1) for ChAdOx1 (after 2,320,535 ChAdOx1 first doses). The adjusted incidence rate ratio was 9.68 (3.46-34.98) for ChAdOx1 compared to mRNA-based vaccines and 3.14 (1.22-10.65) for women compared to non-women. In 26/45 patients with CVT (57.8%), VITT was graded highly probable. Conclusions Given an incidence of 0.22–1.75 per 100,000 person-years for CVT in the general population, these findings point towards a higher risk for CVT after ChAdOx1 vaccination, especially for women.Keywords
Other Versions
- Published version: Version Annals of Neurology, 90, preprints
This publication has 12 references indexed in Scilit:
- Thrombotic Thrombocytopenia after Ad26.COV2.S VaccinationThe New England Journal of Medicine, 2021
- A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 VaccinationPublished by Research Square Platform LLC ,2021
- Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?The Lancet, 2021
- Cerebral Venous ThrombosisStroke, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- Incidence and Mortality of Cerebral Venous Thrombosis in a Norwegian PopulationStroke, 2020
- Cerebral Venous Thrombosis: A Comprehensive ReviewEuropean Neurology, 2020
- Genes Associated With Adult Cerebral Venous ThrombosisStroke, 2011
- A 14-year study of heparin-induced thrombocytopeniaThe American Journal of Medicine, 1996